Author's posts
For Certain Drugs Medicare Selects For Price Negotiation It May Be A Challenge To Get Deeper Discounts Than Current Rebates
For certain drugs Medicare selects for price negotiation it may be difficult to achieve deeper discounts than the rebates these pharmaceuticals currently face.
New Classes Of Obesity Drugs Face Strong Headwinds From Insurers
There’s certainly plenty of demand for and hype around the new wave of weight loss agents. But insurers are pulling back on coverage of these products.
New Classes Of Obesity Drugs Face Strong Headwinds From Insurers
There’s certainly plenty of demand for and hype around the new wave of weight loss agents. But insurers are pulling back on coverage of these products.
As Medicare Broadens Coverage Of Alzheimer’s Disease Drug Leqembi, Details Emerge Regarding What Access Entails
As CMS expands coverage of Leqembi it’s unclear how patient registries will work, how comprehensive scan coverage will be, and whether local carriers have any discretion.
Excessive Heat Can Kill, But For Now Extreme Cold Causes More Fatalities
As the planet heats up, the number of heat-related deaths increase and cold-related deaths decrease. The rate of decrease in deaths due to cold is faster.
Worsening Cancer Drug Shortages Are A Public Health Emergency
Cancer drug shortages aren’t new. Nor are the proposed solutions. But the critical nature of the public health emergency may serve as a call to federal government action.
Report Alleges Narcan Revived Madonna, But Drug’s Use Raises Questions
Because Narcan isn’t typically used in instances of septic shock, the public is left with more questions than answers regarding its alleged use in Madonna’s case.
Cell And Gene Therapies Face Persistent Manufacturing Capacity Constraints
The increasing numbers of cell and gene therapy pipeline candidates, along with a steady growth of new approvals, are stretching manufacturing capacity to its limits.
Poll Suggests Limits To What Most Americans Are Willing To Spend On New Wave Of Obesity Drugs
The typical American’s willingness to pay amount for the new obesity drugs appears to be quite low in relation to the actual list prices, or even payer co-insurance.
As First Therapeutically Interchangeable Humira-Referenced Biosimilar, Cyltezo Has A Marketing Advantage In U.S.
As the first therapeutically interchangeable Humira-referenced biosimilar Cyltezo may gain a distinct marketing advantage over competitors.
